Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you treat an MDS patient who presents with significant cytopenias who is not a candidate for lenalidomide or luspatercept? How do you initiate an HMA when they are severely neutropenic?
Related Questions
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?
How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?
Are there different strategies you would utilize to monitor and manage potential resistance in patients with CML receiving asciminib?
Does the presence of paraneoplastic pemphigus influence your treatment options in CLL?
How do you approach the outpatient management of bispecific antibody therapy for hematologic malignancies?
Do you forego aspirin use in essential thrombocythemia if they are already on clopidogrel?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
